In Silico Identification and Characterization of Drug Targets in Streptococcus pneumoniae ATCC 700669 (Serotype 23F) by Subtractive Genomics

Tolossa Duguma,Hunduma Dinka
DOI: https://doi.org/10.1155/2024/5917667
2024-01-22
BioMed Research International
Abstract:Streptococcus pneumoniae (S. pneumoniae) is an important pathogen worldwide that causes pneumococcal infections which are related to high rates of morbidity and mortality especially in young children, older adults, and immune-compromised persons. Antibiotic resistance in S. pneumoniae is a serious problem across the world from time to time, resulting in treatment failure and diminished value of older medicines. Therefore, the objective of this study was to identify new putative drug targets against S. pneumoniae serotype 23F by using subtractive genomics. By using bioinformatics tools such as NCBI, UniProt KB, PDB, KEGG, DEG, PSORTb, CD hit, DrugBank database, and other softwares, proteins involved in unique metabolic pathways of S. pneumoniae serotype 23F were studied. The result indicates that this serotype consists of 97 metabolic pathways of which 74 are common with that of human, and 23 pathways are unique to the serotype 23F. After investigation and analysis of essentiality, nonhomology, subcellular localization, having drug targets, and enzymatic activity, four proteins were prioritized as druggable targets. These druggable proteins include UDP-N-acetylglucosamine 1-carboxyvinyltransferase, UDP-N-acetyl muramate dehydrogenase, D-alanine-D-alanine ligase, and alanine racemase that are found in S. pneumoniae serotype 23F. All these four proteins are essential, are nonhomologous with human proteins, have drug targets, and are located in cell cytoplasm. Therefore, the authors recommend these proteins to be used for efficient drug design against S. pneumoniae serotype 23F after experimental validation for essentiality and druggability.
biotechnology & applied microbiology,medicine, research & experimental
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to identify and characterize new drug targets in Streptococcus pneumoniae ATCC 700669 (serotype 23F) through the subtractive genomics method. Specifically, the research aims to: 1. **Identify new potential drug targets**: As the resistance of Streptococcus pneumoniae to antibiotics is becoming more and more serious, leading to treatment failures and the devaluation of old drugs, it is necessary to search for new drug targets to develop new drugs against Streptococcus pneumoniae. 2. **Utilize bioinformatics tools**: The research used a variety of bioinformatics tools, such as NCBI, UniProt KB, PDB, KEGG, DEG, PSORTb, CD - hit and DrugBank databases, as well as related software, to study the proteins involved in unique metabolic pathways in Streptococcus pneumoniae serotype 23F. 3. **Screen and prioritize potential drug targets**: Through the analysis of the essentiality, non - homology, subcellular localization, the existence of drug targets and enzyme activity of proteins, four proteins were finally determined as drug targets with priority. These proteins are: - **UDP - N - acetylglucosamine 1 - carboxyvinyltransferase** - **UDP - N - acetylmuramate dehydrogenase** - **D - alanine - D - alanine ligase** - **Alanine racemase** 4. **Verify and recommend**: All of these four proteins are essential, have no homology with human proteins, have drug targets, and are located in the cytoplasm. The authors suggest that after experimental verification of their essentiality and drug accessibility, they can be used for the efficient design of drugs against Streptococcus pneumoniae serotype 23F. In conclusion, this research aims to identify and characterize new drug targets through a systematic method to address the antibiotic resistance problem of Streptococcus pneumoniae.